poisar

Stocks · News reference

Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday

BenzingaAvi Kapoor

Wall St analysts changed outlook on top names. KBW cut AON PT to $400, Barclay's cut T PT to $24, MS cut ROL PT to $65, GS cut SAM PT to $169, BofA raised ALLY PT to $53, Citi raised EW PT to $110, Wells Fargo raised MRK PT to $150, Jefferies raised ENVA PT.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolJames Brumley

    Loan Delinquencies Edge Lower in Q2, but Some Remain at Very High Levels. Here's What It Means for Investors.

    While overall U.S. loan delinquencies declined in Q2 2026, subprime loans remain at multiyear highs, revealing a K-shaped economic recovery where affluent consumers thrive while lower-income households struggle. Mortgage and auto loan delinquencies are rising, with particular pressure on subprime borrowers facing affordability challenges, inflation, and a weakening job market.

  2. The Motley FoolMatt Frankel, Cfp®

    Berkshire Hathaway Just Sold 3 Bank Stocks. Here’s Why Investors Should Take Notice

    Berkshire Hathaway reduced its positions in three bank stocks during Q2 2026: Capital One (58% reduction), Bank of America ($1.7B sale), and Ally Financial (7% reduction). While the exact reasons are unclear, potential factors include concerns about consumer credit deterioration, interest rate risks, and profit-taking in a well-performing financial sector. Berkshire remains heavily invested in banks despite these sales.

  3. Zacks Investment ResearchNa

    Aon's $17 Billion USI Deal: A Costly Bet on Middle-Market Growth

    Aon is acquiring USI Insurance Services from KKR for $17 billion to expand its U.S. middle-market insurance brokerage footprint. The deal, expected to close in Q4 2026, will add specialty insurance access and analytics capabilities while generating approximately $395 million in annual EBITDA synergies. EPS accretion is projected for 2028, though the transaction requires significant debt financing and suspension of share repurchases in the near term.